Nine KUSKOP initiatives boost Indian community under Madani govt
'Over 9,000 Indian entrepreneurs have benefited from financing and development programs this year alone,' Ramanan stated in a Facebook post. Key schemes include SPUMI, PENN for women, BRIEF-i financing, and Vanigham support for small businesses.
The ministry also launched Vanakam Madani, i-BAP accelerators, and EIP 2024 to foster entrepreneurship, alongside grants for places of worship. Ramanan stressed these are 'not just numbers but real commitments' to integrate the community into national progress.
'Empowerment is ongoing work with measurable outcomes,' he added, noting Kuskop is evaluating new projects for future rollout. The deputy minister pledged to monitor implementation closely, ensuring efficient service delivery. - Bernama
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
an hour ago
- The Star
Long-short model pays off for India
SELL-SIDE analysts appear to have emerged as a more valuable resource for investors in India than in any other major market. To some observers, structural idiosyncrasies in the nation's US$5.4 trillion stock market are giving skilled stock-pickers an edge. A long-short strategy model that involves buying the top quintile of stocks most favoured by analysts in an index of the largest 200 Indian firms, while simultaneously shorting the bottom quintile would have returned 105% over the past decade, data analysed by Bloomberg News shows.
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
Malaysia Sun
9 hours ago
- Malaysia Sun
India's semiconductor vision gathers momentum with 3nm chip design and talent development initiatives
New Delhi [India], July 25 (ANI): India is home to nearly 20 per cent of the world's chip design engineers and building on this strong talent base, the government is facilitating the development of a complete semiconductor ecosystem in India, Union Minister of State for Electronics and Information Technology, Jitin Prasada, informed Lok Sabha on Friday. Leading semiconductor companies have established chip design and research centers in India. A 3nm semiconductor chip designed in India was recently unveiled, the minister said. It showcases the technical capabilities of Indian engineers and importance of Indian design centres in global semiconductor industry. To foster talent development in the semiconductor chip design, the Government has launched several initiatives, such as, new curriculum by All India Council for Technical Education (AICTE) for VLSI Design and Technology, Integrated Circuit (IC) manufacturing; developing 85,000 skilled manpower in semiconductor design sector & providing EDA tools to design semiconductor chips; 45,000+ students from 100 institutions enrolled so far; Besides, a Skilled Manpower Advanced Research and Training (SMART) Lab at NIELIT Calicut is being undertaken to train 1 lakh engineers nation-wide with 44,000+ engineers already trained; collaboration with industry and universities such as Lam Research, IBM and Purdue University. India is leveraging its large talent pool, global semiconductor design companies are now rapidly expanding their workforce in India to design cutting-edge chips. Under Semicon India programme, a total outlay of Rs 76,000 crore was approved for catalysing semiconductor and display manufacturing ecosystem in India. Six (6) semiconductor manufacturing and 22 design-linked incentive (DLI) projects have been approved 72 companies are provided chip design infrastructure such as EDA tools & FPGA (Field Programmable Gate Array) boards from Synopsys, Cadence, Siemens, etc. Access to the Post Silicon Validation and Testing and Packaging Support is also being provided, the minister noted. (ANI)
